TECOBIOSCIENCES GMBH

Their core work

TecoBioSciences is a German biotech SME specializing in preclinical and diagnostic technologies for cancer treatment and monitoring. Their work spans image-guided surgery support, MRI-compatible nanomaterials, RNA-based therapeutics, and biosafety assays. They contribute applied bioscience expertise to large international research consortia through MSCA staff exchange and training networks, acting as an industry bridge between academic research and translational biomedical applications.

What they specialise in

How they've shifted over time

In their early H2020 phase (2015–2018), TecoBioSciences concentrated on surgical oncology — specifically image-guided surgery and post-operative immunotherapy through PRISAR and ISPIC. From 2020 onward, their focus broadened significantly: they moved toward non-invasive cancer monitoring (watch-and-wait strategies in PRISAR2), advanced MRI nanomaterials (SENATOR), RNA therapeutics (cONCReTE), and elderly well-being technologies (RISE-WELL). The trajectory shows a clear shift from interventional surgical support toward diagnostics, monitoring, and less invasive therapeutic approaches.

Moving steadily from surgical intervention tools toward diagnostic monitoring, biosafety assays, and emerging RNA therapeutics — positioning for the growing demand in personalized and less invasive cancer care.

How they like to work

TecoBioSciences operates exclusively as a participant, never leading consortia — consistent with an SME contributing specialized industry know-how to academically driven projects. With 69 unique partners across 15 countries and 6 out of 9 projects being MSCA-RISE (staff exchange), they function as an industry host for researcher mobility, offering practical biotech environments for training and knowledge transfer. This makes them an accessible, low-friction partner: experienced in multi-national consortia and accustomed to supporting research networks without seeking the administrative burden of coordination.

Extensive European network spanning 69 unique consortium partners across 15 countries, built primarily through MSCA staff exchange programs. Their heavy RISE participation means deep connections to universities and research institutes across the EU and associated countries.

What sets them apart

TecoBioSciences occupies a rare niche: a private biotech SME that consistently participates in Marie Skłodowska-Curie mobility programs, making them an industry training ground for early-career researchers in biomedical sciences. Their project portfolio shows unusual thematic coherence for an SME — a clear cancer-to-diagnostics pipeline built over nine projects. For consortium builders, they offer a German SME base with genuine biotech lab capacity for staff secondments, plus proven ability to work across diverse academic partnerships without coordination overhead.

Highlights from their portfolio

• ISPIC
  Highest individual funding (EUR 249,216) — focused on combining image-guided surgery with personalized immunotherapy, representing TecoBio's deepest single-project investment.
• PRISAR2
  Direct continuation of their earliest project PRISAR, showing a strategic pivot from surgical imaging to proactive cancer monitoring via watch-and-wait strategies — a clear evolution in their cancer expertise.
• SENATOR
  Expansion into advanced MRI with 19F perfluorocarbon nanomaterials — a technically distinctive area that differentiates them from standard biotech diagnostic companies.